These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

411 related items for PubMed ID: 30048391

  • 1. Effectiveness of Canakinumab in Colchicine- and Anakinra-Resistant or -Intolerant Adult Familial Mediterranean Fever Patients: A Single-Center Real-Life Study.
    Babaoglu H, Varan O, Kucuk H, Atas N, Satis H, Salman R, Ozturk MA, Goker B, Tufan A, Haznedaroglu S.
    J Clin Rheumatol; 2020 Jan; 26(1):7-13. PubMed ID: 30048391
    [Abstract] [Full Text] [Related]

  • 2. Canakinumab is effective in patients with familial Mediterranean fever resistant and intolerant to the colchicine and/or anakinra treatment.
    Karabulut Y, Gezer HH, Duruöz MT.
    Rheumatol Int; 2022 Jan; 42(1):81-86. PubMed ID: 34550430
    [Abstract] [Full Text] [Related]

  • 3. Assessment of effectiveness of anakinra and canakinumab in patients with colchicine-resistant/unresponsive familial Mediterranean fever.
    Şahin A, Derin ME, Albayrak F, Karakaş B, Karagöz Y.
    Adv Rheumatol; 2020 Jan 30; 60(1):12. PubMed ID: 32000860
    [Abstract] [Full Text] [Related]

  • 4. Interventions for reducing inflammation in familial Mediterranean fever.
    Yin X, Tian F, Wu B, Xu T.
    Cochrane Database Syst Rev; 2022 Mar 29; 3(3):CD010893. PubMed ID: 35349164
    [Abstract] [Full Text] [Related]

  • 5. Effect of anti-interleukin-1 treatment on quality of life in children with colchicine-resistant familial Mediterranean fever: A single-center experience.
    Kurt T, Aydın F, Nilüfer Tekgöz P, Sezer M, Uncu N, Çelikel Acar B.
    Int J Rheum Dis; 2020 Jul 29; 23(7):977-981. PubMed ID: 32558310
    [Abstract] [Full Text] [Related]

  • 6. Treatment of colchicine-resistant Familial Mediterranean fever in children and adolescents.
    Eroglu FK, Beşbaş N, Topaloglu R, Ozen S.
    Rheumatol Int; 2015 Oct 29; 35(10):1733-7. PubMed ID: 26001859
    [Abstract] [Full Text] [Related]

  • 7. Anti-interleukin-1 treatment in 26 patients with refractory familial mediterranean fever.
    Kucuksahin O, Yildizgoren MT, Ilgen U, Ates A, Kinikli G, Turgay M, Erten S.
    Mod Rheumatol; 2017 Mar 29; 27(2):350-355. PubMed ID: 27328763
    [Abstract] [Full Text] [Related]

  • 8. Longterm Beneficial Effect of Canakinumab in Colchicine-resistant Familial Mediterranean Fever.
    Laskari K, Boura P, Dalekos GN, Garyfallos A, Karokis D, Pikazis D, Settas L, Skarantavos G, Tsitsami E, Sfikakis PP.
    J Rheumatol; 2017 Jan 29; 44(1):102-109. PubMed ID: 28042127
    [Abstract] [Full Text] [Related]

  • 9. Real-life data on tapering or discontinuation of canakinumab therapy in patients with familial Mediterranean fever.
    Karabulut Y, Gezer HH, Öz N, Esen İ, Duruöz MT.
    Rheumatol Int; 2022 Dec 29; 42(12):2211-2219. PubMed ID: 36048189
    [Abstract] [Full Text] [Related]

  • 10. Anti-IL1 treatment in colchicine-resistant paediatric FMF patients: real life data from the HELIOS registry.
    Sag E, Akal F, Atalay E, Akca UK, Demir S, Demirel D, Batu ED, Bilginer Y, Ozen S.
    Rheumatology (Oxford); 2020 Nov 01; 59(11):3324-3329. PubMed ID: 32306038
    [Abstract] [Full Text] [Related]

  • 11. Outcomes of Canakinumab Treatment in Recipients of Kidney Transplant With Familial Mediterranean Fever: A Case Series.
    Sendogan DO, Saritas H, Kumru G, Eyupoglu S, Sadioglu RE, Tuzuner A, Sengul S, Keven K.
    Transplant Proc; 2019 Sep 01; 51(7):2292-2294. PubMed ID: 31400972
    [Abstract] [Full Text] [Related]

  • 12. Anti-interleukin-1 treatment among patients with familial Mediterranean fever resistant to colchicine treatment. Retrospective analysis.
    Sargin G, Kose R, Senturk T.
    Sao Paulo Med J; 2019 May 08; 137(1):39-44. PubMed ID: 31116269
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of canakinumab for colchicine-resistant or colchicine-intolerant familial Mediterranean fever: A single-centre observational study.
    Tomokawa T, Koga T, Endo Y, Michitsuji T, Kawakami A.
    Mod Rheumatol; 2022 Jul 01; 32(4):797-802. PubMed ID: 34897516
    [Abstract] [Full Text] [Related]

  • 14. Anti-IL-1 treatment in familial Mediterranean fever and related amyloidosis.
    Özçakar ZB, Özdel S, Yılmaz S, Kurt-Şükür ED, Ekim M, Yalçınkaya F.
    Clin Rheumatol; 2016 Feb 01; 35(2):441-6. PubMed ID: 25213327
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of interleukin-1 inhibitors in familial Mediterranean fever patients complicated with amyloidosis.
    Varan Ö, Kucuk H, Babaoglu H, Guven SC, Ozturk MA, Haznedaroglu S, Goker B, Tufan A.
    Mod Rheumatol; 2019 Mar 01; 29(2):363-366. PubMed ID: 29578360
    [Abstract] [Full Text] [Related]

  • 16. Successful management of colchicine resistant familial Mediterranean fever patients with a standardized canakinumab treatment protocol: a case series and literature review.
    Eren Akarcan S, Dogantan S, Edeer Karaca N, Aksu G, Kutukculer N.
    Rheumatol Int; 2020 Jan 01; 40(1):161-168. PubMed ID: 31273456
    [Abstract] [Full Text] [Related]

  • 17. Long-term safety and efficacy of anakinra and canakinumab in patients with familial Mediterranean fever: a single-centre real-life study with 101 patients.
    Atas N, Eroglu GA, Sodan HN, Ozturk BO, Babaoglu H, Satis H, Karadeniz H, Guler AA, Salman RB, Goker B, Ozturk MA, Haznedaroglu S, Tufan A.
    Clin Exp Rheumatol; 2021 Jan 01; 39 Suppl 132(5):30-36. PubMed ID: 34251317
    [Abstract] [Full Text] [Related]

  • 18. Effect of interleukin-1 inhibition in a cohort of patients with colchicine-resistant familial Mediterranean fever treated consecutively with anakinra and canakinumab.
    Druyan A, Giat E, Livneh A, Grossman C, Ben-Zvi I, Lidar M.
    Clin Exp Rheumatol; 2021 Jan 01; 39 Suppl 132(5):75-79. PubMed ID: 34369359
    [Abstract] [Full Text] [Related]

  • 19. Comparison of the efficacy and safety of tocilizumab for colchicine-resistant or colchicine-intolerant familial Mediterranean fever: study protocol for an investigator-initiated, multicenter, randomized, double-blind, placebo-controlled trial.
    Koga T, Sato S, Miyamoto J, Hagimori N, Kawazoe Y, Arinaga K, Fukushima C, Yamamoto H, Kawakami A.
    Trials; 2018 Dec 29; 19(1):715. PubMed ID: 30594222
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of anti-interleukin-1 in children with colchicine-resistant familial Mediterranean fever.
    Erkilet HK, Gezgin Yildirim D, Esmeray P, Söylemezoğlu O.
    Pediatr Int; 2023 Dec 29; 65(1):e15588. PubMed ID: 37658625
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.